MRNA · 8-K · 20260731PR000147
Capital Expenditures Program
Moderna, Inc. · 2026-07-31 · Importance 70 · Surprise 40 · No source text
Moderna expects 2026 capital expenditures of $0.2 billion to $0.3 billion. Six-month 2026 purchases of property, plant and equipment were $99 million, compared with $120 million in the first six months of 2025. The company reported $2.059 billion of net property, plant and equipment at June 30, 2026, compared with $2.134 billion at December 31, 2025. Six-month investing activities generated $253 million of net cash, including $1.442 billion of marketable-securities maturities and $814 million of securities-sale proceeds.
Key facts
- Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion. source
- Net cash (used in) provided by investing activities for the six months ended June 30, 2026 was $253 million provided. source
- Purchases of property, plant and equipment for the six months ended June 30, 2026 were $99 million. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | — | Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion. |
| cash | negative | committed | — | Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion. |
| cash | positive | realized | — | Net cash (used in) provided by investing activities for the six months ended June 30, 2026 was $253 million provided. |